Shareholding disclosure

T&D - Trust Directors S.r.l

Declared position

17.77%

Threshold

Crossed upwards

Timeline

Published

04.07.2019

Transaction

01.07.2019

Transfer date

10.07.2019

Voting rights breakdown

Voting rights acquired17.77%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAJ72000B4

Beneficial owner

T&D - Trust Directors S.r.l

Declared address

T&D - Trust Directors S.r.l., Milano

Exceeding 15% threshold

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

T&D - Trust Directors S.r.l

IGEA Pharma N.V.04.07.2019TAJ72000B4

Disclosure summary

T&D - Trust Directors S.r.l disclosed a holding in IGEA Pharma N.V. on the acquisition side, published by SIX Exchange Regulation on 04.07.2019, at 17.77% of voting rights. Notice category: Single shareholder.

Disclosed position

17.77%

Voting rights acquired

Voting rights acquired17.77%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

T&D - Trust Directors S.r.l disclosed a holding in IGEA Pharma N.V., published on 04.07.2019.

Publication date04.07.2019

Transaction date01.07.2019

Transfer date10.07.2019

Issuing companyIGEA Pharma N.V.

Beneficial ownerT&D - Trust Directors S.r.l

Declared addressT&D - Trust Directors S.r.l., Milano

CategorySingle shareholder

Voting rights acquired17.77%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAJ72000B4

Conditions

Exceeding 15% threshold

Source: SIX Exchange Regulation · Publication date: 04.07.2019

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open